Morgan Stanley Has Lowered Expectations for Personalis (NASDAQ:PSNL) Stock Price

Personalis (NASDAQ:PSNL) had its target price lowered by equities research analysts at Morgan Stanley from $11.00 to $10.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s price objective suggests a potential upside of 20.34% from the stock’s previous close.

Several other equities research analysts have also issued reports on PSNL. Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Lake Street Capital reissued a “buy” rating and issued a $11.00 price objective on shares of Personalis in a research report on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Thursday, January 22nd. Needham & Company LLC upped their target price on Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Finally, Guggenheim raised their price target on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $11.00.

Personalis Price Performance

Shares of Personalis stock traded down $0.62 on Thursday, reaching $8.31. The company had a trading volume of 841,006 shares, compared to its average volume of 1,358,344. The firm has a market cap of $869.49 million, a price-to-earnings ratio of -9.13 and a beta of 2.02. The firm’s 50-day moving average price is $8.85 and its two-hundred day moving average price is $8.07. Personalis has a 1 year low of $2.83 and a 1 year high of $11.50.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. Personalis had a negative return on equity of 39.13% and a negative net margin of 116.69%.The company had revenue of $17.35 million during the quarter, compared to the consensus estimate of $17.12 million. As a group, analysts anticipate that Personalis will post -1.4 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada raised its position in Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after purchasing an additional 2,395 shares in the last quarter. Dynamic Technology Lab Private Ltd raised its holdings in shares of Personalis by 75.6% in the first quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock valued at $269,000 after acquiring an additional 33,044 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Personalis by 55.7% in the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock valued at $998,000 after acquiring an additional 101,706 shares in the last quarter. Focus Partners Wealth purchased a new stake in Personalis in the first quarter worth about $47,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Personalis during the 2nd quarter worth about $451,000. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.